NDAORALCAPSULE
Approved
Mar 1967
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
3
Data completeness
3/8 — Basic
PONSTEL (mefenamic acid) by Molecular Devices is cyclooxygenase inhibitors [moa]. First approved in 1967.
Drug data last refreshed Yesterday
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
PONSTEL is an oral NSAID containing mefenamic acid that works by inhibiting cyclooxygenase enzymes to reduce prostaglandin synthesis. It is indicated specifically for dysmenorrhea (painful menstruation) and is administered as an oral capsule. The drug has been approved since 1967 and represents a mature, well-established treatment option in women's health.
LOE Approaching
As a mature product approaching loss of exclusivity with minimal Part D spending data, the brand team is likely focused on defending market share against generics and managing decline rather than growth initiatives.
Mechanism of Action
Cyclooxygenase Inhibitors
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (3)
A Study of Soticlestat With Itraconazole and Mefenamic Acid in Healthy Adults
Started Oct 2021
28 enrolled
Healthy Volunteers
Interaction Study to Evaluate the Effects of Mefenamic Acid on the Pharmacokinetics and Pharmacodynamics of Sotagliflozin in Healthy Male and Female Subjects
Started Mar 2017
16 enrolled
Diabetes Mellitus
Efficacy and Safety Study of Meloxicam Versus Mefenamic Acid in Patients With Dysmenorrhea
Started Jan 1998
337 enrolled
Dysmenorrhea
Career Relevance
Working on PONSTEL offers limited growth opportunity and minimal linked job openings, reflecting a mature product in decline. Career positions focus on managing transition to generics, protecting market share, and operational efficiency rather than innovation or expansion.
Worked on PONSTEL at Molecular Devices? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.